- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03078608
POEM (Practice Of Embracing Each Moment) STUDY (POEM)
A Pilot Study of a Mobile/Online-based Mindfulness Intervention for Cancer Patients and Caregivers
A cancer diagnosis is extremely stressful, emotionally challenging, and often life-altering for both patients and their loved ones. Although more than one-third of patients experience distress, doctors are typically at a loss as to how to help patients and their families manage these emotional challenges. Mindfulness-based programs, including meditation, are offered at major medical centers in the US and have been found to help reduce stress and improve quality of life among cancer patients. However, these classes often require 30+ hours of in-person instruction over 8 weeks, which is neither practical nor feasible for patients undergoing chemotherapy due to side effects and scheduling conflicts.
This study will test whether an 8-week mobile app-based mindfulness program is accepted and useful for patients who have recently received chemotherapy and their loved ones. It will also test whether it is feasible to randomize participants into three groups: intervention, active control (receiving progressive muscle relaxation through the same app) and a wait list control group (will receive the meditation intervention 8 weeks later), so that a future study can test whether mindfulness intervention can help reduce stress and improve quality of life. Because many Americans own smartphone or tablet, an app that can teach stress reduction techniques at home or at infusion clinics has great potential to address emotional needs that providers often cannot.
The study will also include caregivers of patients who have recently received chemotherapy as research has shown that caregivers tend to show high levels of stress and depression and worse physical health compared to non-caregivers. The negative effects of caregiving are most pronounced in caregivers of patients with cancer. However, little support is directed to caregivers as most medical attention goes toward the patients. The patient-caregiver relationship may serve as a source of mutual support and a surrogate for community, which is traditionally considered to be an essential ingredient for sustaining mindfulness practices.
If this study is successful, it will justify a larger trial to determine if use of a mindfulness app is effective in reducing stress and improving quality of life for cancer patients and caregivers. If effective, this low-cost stress reduction strategy could be distributed and used for all types and stages of cancer patients and their caregivers, anywhere, any time, helping to improve the quality of life of the many individuals affected by cancer.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Oakland, California, United States, 94611
- Kaiser Permanente Northern California
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- active member of Kaiser Permanente Northern California
- a diagnosis of cancer, and currently undergoing chemotherapy or completed chemotherapy in the past 6 months at time of recruitment
- English literacy/fluency, access to a smartphone, a tablet (e.g., iPad) or a computer with internet
- Caregivers: a partner, other family member, or a close friend who identify him/herself as the patient's primary unpaid caregiver. English literacy/fluency, access to a smartphone, a tablet (e.g., iPad) or a computer with internet access
Exclusion Criteria:
- Deafness
- severe mental illness
- Hospital Anxiety and Depression Scale score <8 or >14 on either anxiety or depression scale (patient only)
- current stress reduction practice
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm
Participants in the intervention arm will receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks.
|
Mobile app-based/online mindfulness meditation program
|
Active Comparator: Active control arm
Participants in this arm will receive access to a mobile app-based/online progressive muscle relaxation (PMR) program and asked to practice PMR daily for 8 weeks.
|
Mobile app-based/online progressive muscle relaxation program
|
Other: Wait list control arm
Participants in the wait list control arm will also receive access to a mobile app-based/online mindfulness meditation program and asked to practice meditation daily for 8 weeks, but they will not receive access to the program until after the intervention group completes the intervention (8 weeks later).
|
Mobile app-based/online mindfulness meditation program
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in anxiety and depression
Time Frame: Baseline to 8 weeks
|
The Hospital Anxiety and Depression Scale (HADS) will be used to measure both anxiety and depression.
This scale is frequently used to assess psychosocial outcomes in cancer patients.
The HADS is a 14-item self-report measurement tool designed for use in medical outpatient settings to assess depression and anxiety.
Each subscale is scored from 0 to 21, with higher scores indicating greater distress; 0-7 is generally considered "normal," 8-10 "mild," 11-14 "moderate," and 15-21 "severe" symptoms.
|
Baseline to 8 weeks
|
Change in anxiety and depression
Time Frame: Baseline to 16 weeks
|
The Hospital Anxiety and Depression Scale (HADS) will be used to measure both anxiety and depression.
This scale is frequently used to assess psychosocial outcomes in cancer patients.
The HADS is a 14-item self-report measurement tool designed for use in medical outpatient settings to assess depression and anxiety.
Each subscale is scored from 0 to 21, with higher scores indicating greater distress; 0-7 is generally considered "normal," 8-10 "mild," 11-14 "moderate," and 15-21 "severe" symptoms.
|
Baseline to 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in distress
Time Frame: Baseline to 8 weeks
|
The National Comprehensive Cancer Network Distress Thermometer will be used to assess current distress level.
Respondents are asked to rate their level of distress during the past week by circling a number on an image of a thermometer, with 0 indicating "no distress" and 10 "extreme distress".
|
Baseline to 8 weeks
|
Change in distress
Time Frame: Baseline to 16 weeks
|
The National Comprehensive Cancer Network Distress Thermometer will be used to assess current distress level.
Respondents are asked to rate their level of distress during the past week by circling a number on an image of a thermometer, with 0 indicating "no distress" and 10 "extreme distress".
|
Baseline to 16 weeks
|
Change in fatigue
Time Frame: Baseline to 8 weeks
|
The Brief Fatigue Inventory assesses the severity and impact of cancer-related fatigue, asks about current level of fatigue, average and worst level of fatigue in the past 24 hours, and extent to which fatigue interfered with various aspects of life in the past 24 hours (e.g., mood, walking ability) on a 10-point Likert scale.
A global fatigue score is calculated by averaging all items (ranging from 0 to 10).
A higher score represents greater severity and impact of fatigue.
|
Baseline to 8 weeks
|
Change in fatigue
Time Frame: Baseline to 16 weeks
|
The Brief Fatigue Inventory assesses the severity and impact of cancer-related fatigue, asks about current level of fatigue, average and worst level of fatigue in the past 24 hours, and extent to which fatigue interfered with various aspects of life in the past 24 hours (e.g., mood, walking ability) on a 10-point Likert scale.
A global fatigue score is calculated by averaging all items (ranging from 0 to 10).
A higher score represents greater severity and impact of fatigue.
|
Baseline to 16 weeks
|
Change in Pain
Time Frame: Baseline to 8 weeks
|
The Patient-Reported Outcomes Measurement Information System(PROMIS) pain scale will be used to measure the self-reported consequences of pain on relevant aspects of one's life.
This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities.
|
Baseline to 8 weeks
|
Change in Pain
Time Frame: Baseline to 16 weeks
|
The Patient-Reported Outcomes Measurement Information System(PROMIS) pain scale will be used to measure the self-reported consequences of pain on relevant aspects of one's life.
This includes the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities.
|
Baseline to 16 weeks
|
Change in sleep quality
Time Frame: Baseline to 8 weeks
|
The Patient-Reported Outcomes Measurement Information System(PROMIS) Sleep-Related Impairment scale measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness.
|
Baseline to 8 weeks
|
Change in sleep quality
Time Frame: Baseline to 16 weeks
|
The Patient-Reported Outcomes Measurement Information System(PROMIS) Sleep-Related Impairment scale measures self-reported perceptions of alertness, sleepiness, and tiredness during usual waking hours, and the perceived functional impairments during wakefulness associated with sleep problems or impaired alertness.
|
Baseline to 16 weeks
|
Change in mindfulness
Time Frame: Baseline to 8 weeks
|
Mindfulness will be measured using the Five Facet Mindfulness Questionnaire
|
Baseline to 8 weeks
|
Change in mindfulness
Time Frame: Baseline to 16 weeks
|
Mindfulness will be measured using the Five Facet Mindfulness Questionnaire
|
Baseline to 16 weeks
|
Change in Post Traumatic Growth
Time Frame: Baseline to 8 weeks
|
Self-reported posttraumatic growth as a result of having cancer will be measured using the Post Traumatic Growth Inventory.
|
Baseline to 8 weeks
|
Change in Post Traumatic Growth
Time Frame: Baseline to 16 weeks
|
Self-reported posttraumatic growth as a result of having cancer will be measured using the Post Traumatic Growth Inventory.
|
Baseline to 16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ai Kubo, PhD, Kaiser Permanente Northern California, Division of Research
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CN-17-2851
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on Mindfulness meditation program (administered via mobile app)
-
University of ArizonaCompletedAnxiety | Sleep Disturbance | Perceived StressUnited States
-
BaycrestCenter for Aging and Brain Health Innovation; InteraXon, Inc.TerminatedMild Cognitive Impairment | CaregiversCanada
-
University of HawaiiVA Palo Alto Health Care SystemCompletedCancer, Other Than Non-melanoma Skin CancerUnited States
-
University of SaskatchewanRoyal University Hospital FoundationCompletedBreast Reconstruction | Shoulder DysfunctionCanada
-
Northwestern UniversityCompletedDepression | AnxietyUnited States
-
Arizona State UniversityThe University of Texas Health Science Center at San AntonioCompleted
-
The University of Texas Health Science Center at...Arizona State UniversityWithdrawn
-
Queen Mary University of LondonHeadspace UKCompletedChronic Pelvic PainUnited Kingdom
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Completed
-
Baylor College of MedicineThe University of Texas Health Science Center, Houston; TIRR Memorial HermannTerminated